Increased Gastric pH and Bioavailability of Oral Foscarnet in HIV-Infected Males
This phase 1 study aims to investigate how increased gastric pH affects the bioavailability of oral Foscarnet in HIV-infected males.
Ranitidine hydrochloride
+ Foscarnet sodium
Blood-Borne Infections+13
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
Foscarnet is an antiviral compound. Laboratory studies have shown it to be active against HIV. However, only 12 - 22 percent of an oral foscarnet dose is absorbed by the body. Ranitidine suppresses gastric acid output, increasing gastric pH. Thus by increasing gastric pH (decreasing stomach acidity), less foscarnet is expected to be decomposed or broken down in the stomach. Thus, more foscarnet should be absorbed into the body. Six asymptomatic HIV-infected males, or those with limited symptoms of early AIDS-related complex ( ARC ), will receive one dose intravenously of ranitidine in distilled water and one dose of placebo (distilled water alone), followed in 1 hour by foscarnet in oral solution. The order of ranitidine and placebo is randomized and the two foscarnet doses are separated by at least 72 hours. A nasogastric pH probe is placed on each morning of drug administration to monitor gastric pH.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.6 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Male
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria Concurrent Medication: Allowed: Acetaminophen and sedatives. Patient must be able to give informed consent. Exclusion Criteria Patients with the following are excluded: Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight within 2 years prior to study. Unexplained temperature above 38 degrees Celsius on more than 5 consecutive days or on more than 10 days in any 30 days in 2 years prior to expected study entry. Unexplained diarrhea defined by two or more stools/day for at least 14 days during a 120-day interval. Prior Medication: Excluded within 1 week of entry into study: Probenecid, aspirin, or diuretics.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Johns Hopkins Adult AIDS CRS
Baltimore, United StatesOpen Johns Hopkins Adult AIDS CRS in Google Maps